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ABSTRACT
Effects of Anti-viral Acute Phase Response on Hippocampal Glutamate Regulation
Holly Hunsberger
A large body of clinical evidence suggests that viral infections in the periphery
can exacerbate neurodegenerative conditions such as Alzheimer’s disease, Huntington’s,
disease, Parkinson’s disease, multiple sclerosis, and seizures. The underlying
mechanisms of these conditions involve the activation of the acute phase response (APR),
part of the innate immune system, which recognizes viral molecular patterns. As
neighboring cells become infected, inflammatory mediators are released into the
bloodstream and relayed to the central nervous system where they produce a “mirror”
inflammatory response. To induce the APR, polyinosinic-polycytidylic acid (PIC), a viral
mimetic, is commonly used. PIC produces a robust and transient increase in
inflammatory factors in the brain, which modify neuronal networks leading to behavioral
traits referred to as sickness behavior.
Recent evidence also reveals an increase in kainic acid-induced seizure
hypersusceptibility in PIC-challenged animals. Although the underlying mechanisms for
this seizure hypersusceptibility are not well known, inflammatory mediators produced in
response to PIC can act on excitatory glutamate receptors resulting in increased neuronal
activity. Increased neuronal activity has been implicated in many neurodegenerative
conditions. To examine glutamate’s role in the pathophysiology of seizures after
peripheral insult, microelectrode arrays were employed to measure glutamate levels in the
hippocampus of mice. In Experiment 1, female C57BL/6 mice were i.p. injected with
PIC, and 24 hours later glutamate levels were measured in each subregion of the
hippocampus (DG, CA3, and CA1). PIC-challenge resulted in a robust increase in resting
extracellular glutamate levels. Although potassium-evoked glutamate release was similar
between PIC and saline mice, glutamate clearance was significantly decreased after PICchallenge. These results suggest functional alterations of astrocytes. Electrophysiological
examination of hippocampal slices from PIC-challenged mice revealed an increase in
basal synaptic transmission, increased probability of pre-synaptic glutamate release, and
enhanced long-term potentiation (LTP). Altogether, these results reveal dysregulation of
glutamate homeostasis and enhanced excitatory synaptic transmission, which could
contribute to the seizure hypersusceptibility observed in PIC-challenged mice.
Experiment 1 characterized glutamate neurotransmission in an anesthetized
animal after PIC injection, while Experiment 2 aimed to investigate the relationship
between PIC challenge, glutamate homeostasis, and seizure severity in an awake
behaving animal. MEAs were chronically implanted in the CA1 of the hippocampus to
record tonic glutamate and glutamate transients, or spontaneous glutamate release before,
during, and after KA-induced seizures across four days. Our results revealed an increase
in tonic glutamate levels, an effect that gradually declined across the four days. These
results are congruent with the decrease in seizure activity and inflammatory mediator
levels across days. The most notable finding was that tonic glutamate levels were
predictive of seizure severity as indicated by an increase in the average and cumulative

seizure scores. The results provide greater insight into the mechanisms underlying the
changes that occur during cerebral inflammation and may provide a link between
peripheral insult and the comorbidity of neurodegenerative conditions.
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Chapter 1
The role of glutamate excitatory neurotransmission after peripheral viral challenge
Viral infections activate the acute phase response (APR), the body’s first line of
immune defense (Baumann & Gauldie, 1994), to contain the spread of infection by
initiating a signaling cascade of inflammatory mediators (e.g., cytokines and chemokines)
in the periphery (Cunningham, Campion, Teeling, Felton, & Perry, 2007; Dantzer, 2006;
Dantzer & Kelley, 2007). Following APR, the adaptive immune system works to
reestablish homeostasis and promote healing. These peripherally-generated, blood-borne
inflammatory mediators induce a “mirror” inflammatory response in the brain that
modify the activity of neural networks to ultimately produce a behavioral complex of
adaptive behaviors known as “sickness behavior” (Dantzer & Kelley, 2007; Dantzer,
O'Connor, Freund, Johnson, & Kelley, 2008; G. Konat, 2016; Quan & Banks, 2007).
Though alterations in neural networks, and the resulting sickness behavior, serve to
protect the host, a growing body of evidence suggests these modifications may have
deleterious effects in the presence of other neuropathological conditions. For example,
viral infections in the periphery can exacerbate neurodegenerative conditions including
seizures, Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS),
and Huntington’s disease (HD) in humans (see Perry, Newman, & Cunningham, 2003 for
review). Experimental studies support these findings. Notably, peripheral injection of a
viral mimetic, polyinosinic-polycytidylic acid (PIC), results in robust and protracted
hypersusceptibility to kainic acid (KA) induced seizures in mice (Kirschman,
Borysiewicz, Fil, & Konat, 2011).
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Though the exact mechanisms by which viral infections exacerbate
neurodegenerative conditions are not known, many of the major inflammatory mediators
generated by viral infections have been shown to increase neuronal excitability (Galic,
Riazi, & Pittman, 2012; Hu, Sheng, Ehrlich, Peterson, & Chao, 2000; Riazi et al., 2015;
Viviani et al., 2003) and decrease neuronal inhibition (Stellwagen, Beattie, Seo, &
Malenka, 2005; S. Wang, Q. Cheng, S. Malik, & J. Yang, 2000), both of which may lead
to increased extracellular glutamate concentrations. Given recent evidence linking
glutamatergic hyperactivity to AD (Bakker et al., 2012; Busche et al., 2012; Hunsberger,
Rudy, Batten, Gerhardt, & Reed, 2015; Hunsberger, Weitzner, et al., 2015), PD (Ahmed
et al., 2011; Schapira, 2010), MS (Kostic, Zivkovic, & Stojanovic, 2013), and seizures
(Chapman, 2000; Soukupova et al., 2015), deciphering mechanisms by which peripheral
viral infection elevates extracellular glutamate is critical to the prevention of infectionmediated exacerbations in neurodegenerative conditions. In Experiment 1, we explored
the effects of a single peripheral injection of PIC on glutamate homeostasis and synaptic
transmission. In Experiment 2, we examine the relationships among peripheral infection,
glutamate homeostasis, and KA-induced seizures.
The following review will discuss evidence that peripheral infections exacerbate
neuropathological conditions in both humans and animal models. To elucidate potential
mechanisms, the role of the APR and resultant inflammatory factors in alterations of
neural networks, with a focus on alterations in glutamate excitatory neurotransmission
and homeostasis, will be reviewed.
Peripheral infection and neurodegenerative conditions
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A body of clinical evidence has revealed that peripheral infections are comorbid
with neurodegenerative conditions (Banks & Robinson, 2010; Perry et al., 2003). For
example, AD patients suffering from systemic infection exhibit greater cognitive
impairment (Holmes et al., 2003).When examining twins with AD, those with severe
systemic infection burden develop AD at an earlier age than the corresponding twin (Nee
& Lippa, 1999). In addition, one common characteristic at autopsy of individuals without
dementia that exhibit a heavy beta-amyloid load, a hallmark feature of AD, is lower
levels of pro-inflammatory markers compared to AD patients (Lue, Brachova, Civin, &
Rogers, 1996). Other risk factors for AD include oral infection (Stein, Desrosiers,
Donegan, Yepes, & Kryscio, 2007), helicobacter gut bacteria (Kountouras et al., 2009;
Kountouras et al., 2006), as well as delirium (Murray et al., 1993; Rahkonen,
Luukkainen-Markkula, Paanila, Sivenius, & Sulkava, 2000), which is significantly
correlated with systemic infection (de Rooij, van Munster, Korevaar, & Levi, 2007; van
Munster et al., 2008). Often these infections can lead to or induce delirium in AD
patients. In fact, the most common cause of delirium in elderly patients is infection
(George, Bleasdale, & Singleton, 1997). Together, these studies suggest peripheral
infection exacerbates cognitive dysfunction in AD.
Inflammation and infection also correlate with pathology seen in patients with
MS and PD. Notably, there are significant correlations between the number of relapses
and the number of viral infections in MS patients (O. Andersen, Lygner, Bergstrom,
Andersson, & Vahlne, 1993). Upper respiratory tract infections increase the likelihood of
relapse by 3-fold compared to the non-infected individuals (Edwards, Zvartau, Clarke,
Irving, & Blumhardt, 1998). Respiratory infections, such as pneumonia are the main
3

causes of death in patients with PD (Beyer, Herlofson, Arsland, & Larsen, 2001).
Gastrointestinal infection can also exacerbate the progression of PD (Weller et al., 2005)
possibly via the upregulation of specific inflammatory mediators, which have been
observed in the cerebral spinal fluid (CSF) (Blum-Degen et al., 1995), serum (Dobbs et
al., 1999), and post mortem tissue (Mogi et al., 1994) of those suffering from PD.
Evidence from animal models further supports that the APR is a comorbid factor
in neurodegeneration. For example, a single systemic PIC injection disrupts memory in
the fear conditioning test (CFC) (Kranjac et al., 2012). It also decreases marble
burrowing behavior. This burrowing behavior is increased in aged mice and could be
attributed to an age-dependent increase in inflammatory mediators in the hippocampus
(McLinden et al., 2012). Furthermore, prolonged activation of the APR by repeated
administration of PIC significantly increases levels of the amyloid-beta peptide (Aβ1-42)
in the hippocampus of non-transgenic mice (Weintraub et al., 2014). Moreover,
increasing PIC induced Aβ1-42 burden, a hallmark of AD, is associated with memory
deficits in the CFC (White et al., 2016). Interestingly, maternal immune activation also
results in AD-like pathology in offspring. Systemic PIC injection during gestation causes
offspring to develop AD pathology, including an increase in the amyloid precursor
protein (APP), translocation of the tau protein to dendritic compartments, and a decrease
in working memory (Krstic et al., 2012). If these mice are PIC challenged a second time
in adulthood, gliosis and tau aggregation occur, both of which represent late stage
pathology in AD. In addition, transgenic AD mice injected with PIC exhibit an
accelerated AD plaque deposition (Krstic et al., 2012). Together, these results suggest
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that peripheral PIC injection can lead to AD-like pathology and exacerbate
neurodegenerative pathology that is already present.
It should be noted, however, that these results are not limited to systemic PIC
injections. Many studies examining infection, inflammation, and seizure susceptibility
have used bacterial models, such as lipopolysaccharide (LPS) - a ubiquitus component of
the cell wall of gram negative bacteria, and have observed similar alterations as that
observed with PIC injections (Riazi, Galic, & Pittman, 2010; Sayyah, Javad-Pour, &
Ghazi-Khansari, 2003). For example, elevated Aβ levels are observed in mice injected
systemically with LPS (Ma et al., 2016). LPS challenged mice also exhibit memory
deficits in the Morris Water Maze memory task (Ma et al., 2016), an increase in activated
glycogen synthase kinase 3 beta (GSK3β), which phosphorylates the tau protein, and a
decrease in hippocampal metabolism (Carret-Rebillat et al., 2015), all of which are
observed in AD patients (Leroy, Yilmaz, & Brion, 2007; Possin et al., 2016; Yamaguchi
et al., 1997). Tau hyperphosphorylation is further increased in a transgenic AD mouse
model after LPS injection, an effect that is exacerbated in aged mice (Kitazawa, Oddo,
Yamasaki, Green, & LaFerla, 2005).
Other conditions such as PD and prion disease are also comorbid with viral
infection in animal models. PD is characterized by a loss of dopamine (DA) neurons and
motor impairments (Kakkar & Dahiya, 2015). Injection of either PIC or LPS in animal
models results in neuronal degeneration of dopamine neurons in the substantia nigra (SN)
(Bobyn et al., 2012; Deleidi, Hallett, Koprich, Chung, & Isacson, 2010; Smith et al.,
2015). The loss of SN DA neurons is likely mediated by inflammatory factors, as
blockade of interleukin-1 (IL-1) and tumor necrosis factor-1 (TNF-1) receptors protects
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against LPS-mediated DA loss in the SN (Koprich, Reske-Nielsen, Mithal, & Isacson,
2008; McCoy et al., 2006). Amplified expression of pro-inflammatory mediators is also
associated with accelerated disease progression in the ME7 mouse model of prion disease
following systemic injection of either PIC or LPS (Cunningham, Wilcockson, Campion,
Lunnon, & Perry, 2005; Field, Campion, Warren, Murray, & Cunningham, 2010).
Many of the aforementioned neurodegenerative diseases share a common
characteristic, seizures. Seizures are often comorbid in AD (Chan, Jones, Bush, O'Brien,
& Kwan, 2015), PD (Feddersen et al., 2014), and MS (Allen, Seminog, & Goldacre,
2013) and can appear after infection (Vezzani et al., 2016). The most common cause of
seizures in children is fever (Berg, Darefsky, Holford, & Shinnar, 1998), which results in
the release of cytokines, specifically in the hippocampus (Dube, Vezzani, Behrens,
Bartfai, & Baram, 2005). In addition, individuals suffering from seizures are at an
increased risk for developing neurodegenerative diseases (Ali, Chugh, & Ekdahl, 2015;
Cordonnier, Henon, Derambure, Pasquier, & Leys, 2007). This evidence further supports
the importance of determining the mechanisms of increased seizure susceptibility
following PIC challenge.
As mentioned above, peritoneal injection of PIC renders the brain hyperexcitable,
as seen from increased susceptibility to KA-induced seizures (Kirschman et al., 2011;
Michalovicz & Konat, 2014). Both the extent and duration of status epilepticus (SE) is
significantly increased in PIC-challenged vs. saline-injected control mice.
Intracerebroventricular (ICV) administration of PIC in 14 day-old rats results in greater
susceptibility to lithium pilocarpine- and pentylenetetrazol- induced seizures and memory
deficits in the CFC paradigm (Galic, Riazi, Henderson, Tsutsui, & Pittman, 2009). In
6

addition, maternal PIC challenge renders the offspring more susceptible to seizures.
These mice also exhibit increased hippocampal hyperexcitability, an effect that is rescued
by cytokine antibodies (Pineda et al., 2013). Together, these studies suggest that the
comorbidity of viral infection with neurodegeneration is likely to involve
hyperexcitability as a mechanistic link. This hyperexcitability is likely mediated in part
by changes in the glutamatergic system, a major excitatory neural system in the brain.
Antiviral acute phase response
APR is activated by double-stranded ribonucleic acid (dSRNA), which is an
intermediate of viral replication (Weber, Wagner, Rasmussen, Hartmann, & Paludan,
2006). As the virus replicates, dsRNA species are released from infected cells and
recognized by neighboring cells, which rapidly trigger APR (Jacobs & Langland, 1996;
Kimura-Takeuchi, Majde, Toth, & Krueger, 1992). As an innate immune response, APR
acts in a non specific manner recognizing pathogen associated molecular patterns
(PAMPs) (Jacobs & Langland, 1996). In contrast, the adaptive immune system is highly
specific as seen from the production of antibodies and T cells (den Haan, Arens, & van
Zelm, 2014). PAMPs are molecules recognized by cells of the innate immune system in
the host organism because they are absent in the host. These cells express several
receptors that detect the presence of extra- and intra-cellular dsRNA (Berke, Li, & Modis,
2013), resulting in the generation of type 1 interferons (IFNs) (Isaacs & Lindenmann,
1957), cytokines, chemokines, (Bluthe et al., 1994), and other inflammatory mediators
(Block & Hong, 2005). Interferons belong to a large class of proteins known as
cytokines, which communicate between cells to trigger protective defenses
(Theofilopoulos, Baccala, Beutler, & Kono, 2005). This first line of defense is critical
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for containing the spread of viral infections long before the adaptive immunity against
viral antigens becomes effective.
To study anti-viral APR, synthetic dsRNA is often used in animal models
(Traynor, Majde, Bohnet, & Krueger, 2004). The PIC-based model is advantageous
compared to true viral infections for several reasons. First, in contrast to viral inoculation,
which requires prolonged and nonsynchronous incubation time to elicit the innate
immune response, PIC response is very rapid (Fil, Borysiewicz, & Konat, 2011; Homan,
Zendzian, Schott, Levy, & Adamson, 1972; G. W. Konat, Borysiewicz, Fil, & James,
2009; Michalovicz, Lally, & Konat, 2015), allowing for hourly kinetic analyses. Second,
the biological activity of PIC is restricted to stimulation of the innate immune response
and there are no confounding effects of pathogen–associated tissue damage (Kunzmann,
Kretzschmar, Herrmann, & Wilhelm, 2004). Third, adaptive immunity (e.g., antibodies
and T cells) resulting from ensuing exposure of animals to viral antigens is eliminated
(Fortier et al., 2004). Fifth, PIC is noninfectious, meaning that experiments can be
conveniently performed under standard laboratory conditions (Fortier et al., 2004).
Because PIC challenge is congruent with behavioral effects of peripheral viral infection
in humans (Huckans et al., 2009; Loftis, Huckans, Ruimy, Hinrichs, & Hauser, 2008),
PIC is widely used as a potent inducer of antiviral APR (Guha-Thakurta & Majde, 1997;
Muller et al., 1994).
Peripheral infection and the CNS
The remodeling of neuronal networks seen after peripheral infection are likely
due in part to inflammatory mediators that travel to the brain and target neurons and glia.
These mediators infect the brain via various pathways. The neural route is represented by
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the primary afferent neurons that innervate the body site where the infectious process
takes place (Watkins et al., 1994). The most important afferent responsible for neural
transmission of peripheral signals is the vagus nerve (Bluthe et al., 1994), which extends
from the brain stem to various abdominal organs. Cytokines can also reach the brain
directly through the blood brain barrier (BBB) by transport proteins and endothelial cells
or through circumventricular organs (CVOs) (Dantzer & Kelley, 2007; Vitkovic et al.,
2000). Endothelial cells, which line the inner surface of capillaries in the brain, are very
responsive to proinflammatory cytokines. Once these cells are activated by cytokines, the
BBB integrity declines and more cytokines are released into the brain parenchyma, a
process known as transduction (de Vries et al., 1996; Forster et al., 2008). CVOs are
areas of the brain that are selectively permeable to blood-borne molecules because they
lack the BBB, allowing substances that do not cross the BBB to trigger changes in brain
function (Ganong, 2000).
Once in the brain, cytokines and chemokines act through a variety of mechanisms
that influence changes in glutamate homeostasis. For example, PIC injection results in the
upregulation of over 600 genes in the hippocampus, an area rich in glutamate and
glutamate receptors (Fotuhi, Standaert, Testa, Penney, & Young, 1994), for up to 72
hours (Michalovicz et al., 2015). Many of these genes “mirror” the release of cytokines
and chemokines in the blood and peak at 6 hours after PIC injection and gradually
decline (Cunningham et al., 2007; Fil et al., 2011; G. W. Konat et al., 2009; Michalovicz
& Konat, 2014; Michalovicz et al., 2015). Although many of these genes encode for
inflammatory pathway components, there are a multitude of genes that relate to
excitatory glutamatergic and inhibitory GABAergic neurotransmission (Michalovicz &
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Konat, 2014) and could play a role in the increased seizure susceptibility seen in PIC
challenged mice. Moreover, PIC injection results in a marked increase in N-Methyl-Daspartic acid (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) glutamate receptor subunit expression (Galic et al., 2009), which could also
contribute to the increased hypersusceptibility.
The four major cytokines released into the blood after PIC challenge that also
surge in the brain include interferon β (IFNβ), interleukin 6 (IL-6), IL-1 β, and tumor
necrosis factor alpha (TNFα), all reaching their highest brain concentrations after 3 hours
(Cunningham et al., 2007; Michalovicz & Konat, 2014; Michalovicz et al., 2015). Brain
cells, such as neurons, microglia, and astrocytes, express receptors for all of the
aforementioned cytokines (McCusker & Kelley, 2013).
Inflammatory mediators and glutamate
Cytokines. In the brain, IL-6 exerts its effects on neuronal functioning by inhibiting
long-term potentiation and impairing cognition as seen from mice overexpressing IL-6
(Bellinger, Madamba, Campbell, & Siggins, 1995). Furthermore, these mice have
impaired development of inhibitory synapses and significantly larger numbers of
mushroom-shaped dendritic spines, which are typically connected to excitatory synapses
(Wei et al., 2012). In addition to changing synaptic morphology, IL-6 can cause a
decrease in inhibition of postsynaptic potentials in the CA1 region of the hippocampus
(Wei et al., 2012) and shift the balance between excitation and inhibition by promoting
the former (Garcia-Oscos et al., 2012), which may be the reason that IL-6 has been
implicated in neurodegeneration following epilepsy (Campbell et al., 1993; Kalueff,
Lehtimaki, Ylinen, Honkaniemi, & Peltola, 2004; Samland et al., 2003). Further, IL-6
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and IFNβ initiate a surge in IL-1β and TNFα, creating a forward loop of continuous
cytokine activity (McCusker & Kelley, 2013). This surge in IL-1β activity can increase
the activity of NMDA receptors (Viviani et al., 2003) and reduce the expression of
astrocytic glutamate receptors (GLT-1) that remove glutamate from the extracellular
space (Prow & Irani, 2008), which presumably would increase extracellular glutamate
levels.
The increased seizure susceptibility observed after PIC challenge (Kirschman et
al., 2011; Michalovicz & Konat, 2014) may result from a combination of increased
excitatory pathways and decreased inhibitory pathways resulting in increased levels of
glutamate. A potential source for this excess glutamate is an upregulation of glutaminase,
the main enzyme responsible for glutamate production. Both IL-1β and TNF-α, when
applied to neuronal cultures, increase glutaminase activity, resulting in increased
extracellular glutamate levels and excitotoxicity (Ye et al., 2013). TNF-α can also
increase glutamate signaling by increasing glutamatergic AMPA receptor expression
(Mizuno et al., 2008), while also promoting endocytosis of inhibitory GABA receptors
(Pribiag & Stellwagen, 2013).
IFNβ differs slightly form the other three major cytokines in that it is
neuroprotective and when activated increases glutamate uptake by human fetal astrocytes
(Hu et al., 2000). IFNβ has also been shown to block the production of glutamate and
microglia-induced cell death following LPS stimulation of cortical neuronal and
microglia co-cultures (Jin et al., 2007), while also promoting the secretion of nerve
growth factor (NGF) by endothelial cells (Biernacki et al., 2005). Because IFNβ can
rescue cells from death caused by pro-inflammatory cytokines released from activated
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microglia, IFNβ has been used as a treatment option for relapsing MS patients to reduce
brain atrophy and improve axonal integrity (Q. Wang & Mao-Draayer, 2015).
Interestingly, IFNβ gene expression is fifty percent lower in the hippocampus compared
to the whole brain after PIC injection (Michalovicz & Konat, 2014), suggesting that the
neuroprotective effects of IFNβ are diminished in the hippocampus after PIC.
Chemokines. Several chemokine receptors and their respective ligands are also increased
after PIC injection and appear to play a role in glutamate homeostasis (Fil et al., 2011;
Michalovicz & Konat, 2014). The CXCR3 receptor, upregulated after PIC injection and
expressed on neurons, can increase the activity of neurons when activated by one of its
ligands (i.e., CXCL10) (Nelson & Gruol, 2004). For example, acute activation by
CXCL10 increases spontaneous synaptic activity (Nelson & Gruol, 2004), possibly via
decreases in inhibitory GABA receptors and increases in excitatory glutamate receptors
(Cho, Nelson, Bajova, & Gruol, 2009). Furthermore, prolonged activation of CXCR3
results in a decrease in the cyclic adenosine monophosphate (cAMP) response elementbinding (CREB) protein (Bajova, Nelson, & Gruol, 2008), which plays a role in memory
formation, as well as a decrease in GAD65/57, a marker for inhibitory synapses, and a
decrease in GABAA and GABAB receptor subunit expression (Cho et al., 2009).
Moreover, CXCR3 activation promotes increases in synapsin 1, which has a role in
neurotransmitter release, and NMDA receptor (NR1 subtype), both of which can increase
synaptic activity (Cho et al., 2009). Although prolonged activation by CXCL10 results in
increased neuronal activity, acute activation with this same ligand, leads to a decrease in
LTP in hippocampal slices. (Vlkolinsky, Siggins, Campbell, & Krucker, 2004).
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While CXCR3 activation appears to be associated with NMDA receptors, CXCR2
receptor activation is shown to increase glutamatergic AMPA receptor expression by its
ligands, i.e., CXCL1 and CXCL2 (Lax et al., 2002; J. G. Wang et al., 2008). All of these
receptors and ligands are upregulated after PIC injection (Fil et al., 2011; Michalovicz &
Konat, 2014). Important to glutamate homeostasis is the chemokine, Ccl2. For example,
Ccl2 is increased in patients with pharmacoresistant epilepsy (He et al., 2013).
Furthermore, blocking the Ccl2 receptor, CCR2, decreases seizure activity in mice after
LPS injection (Cerri et al., 2016). Because Ccl2 expression persists up to 72 hours post
PIC injection (Michalovicz & Konat, 2014), this chemokine may be crucial for the
increased seizure activity observed in PIC challenged mice (Kirschman et al., 2011).
Complement system. Of the 625 genes analyzed in the hippocampus following PIC
injection, the complement system pathway exhibits the greatest activation, and this
activation correlates with seizure hypersusceptibility (Michalovicz et al., 2015).
Complement proteins are part of the innate immune system and act by tagging pathogens
for phagocytosis (Sarma & Ward, 2011). There are eight complements upregulated after
PIC, but the greatest increases are observed in complement factor B (CFB), C3, and C6 (
Michalovicz et al., 2015). The complement system can alter the glutamate homeostasts
by suppressing glutamate uptake and increasing presynaptic release of glutamate (Kolev,
Ruseva, Harris, Morgan, & Donev, 2009; Merega, Di Prisco, Lanfranco, Severi, &
Pittaluga, 2014). This system may be a potential mechanism for the hyperexcitability
observed after PIC challenge as complements can increase the total amount of glutamate
in the extracellular space and can exacerbate neurodegeneration (Yanamadala &
Friedlander, 2010). Increases in, complement C3 release are associated with an increase
13

in AMPA membrane expression, synaptic excitation, and impairment of dendritic
morphology, such as dendritic length and complexity (Alexander, Jacob, Bao,
Macdonald, & Quigg, 2005; Lian et al., 2015). Inhibition of the complement C3 receptor
attenuates memory deficits in APP transgenic AD mice (Lian et al., 2015). Furthermore,
mice deficient in C3 develop significantly fewer seizures following viral
encephalomyelitis (Libbey, Kirkman, Wilcox, White, & Fujinami, 2010). In stroke
(Elvington et al., 2012) and AD (Strohmeyer, Shen, & Rogers, 2000), both of which
exhibit a hyperexcitability phenotype, CFB is activated and colocalizes with neurons. The
effects of this colocalization are not well known, but may contribute to cell death and
infarct volume observed after stroke (Elvington et al., 2012).
Chemokines, cytokines, and the complement system activated after peripheral
viral infection may play a vital role in inducing hyperexcitability in the CNS. Activation
of these mediators carries a risk for exacerbating seizures and other neurodegenerative
conditions. Prolonged exposure or further insult could lead to glutamate dysregulation
through increases in glutamate release, decreases in glutamate clearance mechanisms, and
dysfunctioning glutamate receptors. Understanding these mechanisms could provide a
therapeutic target after infection and possibly prevent neurodegenerative pathology. As
mentioned previously, the hippocampus represents the most at risk brain region for
neurodegeneration (Braak & Braak, 1998) and is the origin of seizure activity during
temporal lobe epilepsy in humans (Goldberg & Coulter, 2013) and animals (Lu et al.,
2016). Therefore, the current project will focus on alterations in glutamate levels in three
subregions of the hippocampus following PIC injection.
Hippocampal circuitry
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The hippocampus is one of the first regions affected in AD (Braak & Braak,
1998) and is the ictal site for KA-induced seizures (Perry et al., 2003). This increased
vulnerability may be related to the high concentration of glutamate receptors
(Greenamyre & Young, 1989) that mediate communication of the trisynaptic circuit of
the hippocampus. This circuit is composed of distinct subregions including the dentate
gyrus (DG), cornuammonis 3 (CA3) and cornuammonis 1 (CA1) (Figure 1). Although
the pathway works as a circuit, each subregion has unique characteristics, including
differences in synaptic connectivity, surface expression of glutamate receptors, gene
expression profiles, and levels of glutamate release and clearance following potassium
chloride (KCl)-evoked release (Greene, Borges, & Dingledine, 2009; Gegelashvili &
Schousboe, 1998; Wilson et al., 2005). Information enters this one-way loop via axons of
the entorhinal cortex known as perforant fibers (P. Andersen, Bliss, & Skrede, 1971).
These axons make the loop’s first connection, with the granule cells of the dentate gyrus
(DG) (Lomo, 2009; Sloviter & Lomo, 2012). From these cells, the mossy fibers project to
make the second connection in the CA3 area (Treves & Rolls, 1992). Through the
Schaffer collaterals fibers, the CA3 sends projections to the CA1, which completes the
loop (Amaral, Dolorfo, & Alvarez-Royo, 1991). Interestingly, the CA3 is also a region of
high excitability because approximately 95 percent of the pyramidal cells receive input
from other CA3 pyramidal cells known as recurrent fibers, meaning that the CA3 fires
within its own region to form an associative network (Kandel & Spencer, 1961). The
CA1 region also exhibits intrinsic hyperexcitability in AD mice (Kerrigan, Brown, &
Randall, 2014). Because of these subregion specific alterations, we will examine
glutamate regulation in the DG, CA3, and CA1 separately.
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Kainic acid-induced seizure model
To study the effects of viral infection on glutamate dysregulation, we will use a
KA-induced seizure model (Ben-Ari, 1985). PIC-challenged mice are more susceptible to
KA-induced seizures (Kirschman et al., 2011), and hippocampal inflammatory responses
are exacerbated (Michalovicz & Konat, 2014). KA is a nondegradable analog of
glutamate and potent neurotoxin that exerts its epileptic properties by acting on neuronal
kainic acid receptors (KARs) (Hollmann & Heinemann, 1994; Monaghan & Cotman,
1982). The CA3 pyramidal cells are particularly susceptible to the epileptogenic action of
KA because this area is enriched with high-affinity KA-receptors (Robinson &
Deadwyler, 1981). Upon binding to KARs, KA induces a multitude of cellular events,
including the influx of cellular calcium (Nistri & Cherubini, 1991) and neuronal apoptosis
(Vincent & Mulle, 2009). Although there is no experimental model that reproduces all of
the features of temporal lobe epilepsy (TLE), the KA model induces seizures and
neuropathological lesions that are similar to those occurring in patients with temporal
lobe epilepsy (TLE) (Ben-Ari, Lagowska, Tremblay, & Le Gal La Salle, 1979).
Microelectrode arrays
To study glutamate dysregulation in the DG, CA3, and CA1, we employ a novel
technique, in vivo amperometry coupled to enzyme-based microelectrode arrays (MEAs)
(Figure 2). Although microdialysis is the standard for sampling analyte concentrations in
vivo, this technique suffers from many disadvantages (Westerink, Damsma, Rollema, De
Vries, & Horn, 1987). For example, spatial and temporal limitations of microdialysis
restrict the ability to sample dynamic changes in glutamate near the synapse (Hillered,
Vespa, & Hovda, 2005; Obrenovitch, Urenjak, Zilkha, & Jay, 2000). The large sample
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area (1-4mm in length) often causes damage and limits the detection of neuronal release
(Borland, Shi, Yang, & Michael, 2005; Jaquins-Gerstl & Michael, 2009). In addition, the
low temporal resolution (1–20 min) of microdialysis is inadequate to measure the fast
dynamics of glutamate uptake and clearance (Diamond, 2005). MEAs are advantageous
because they allow for such measures due to their high temporal resolution (10 Hz), low
limit of detection (<0.5 µM), and high spatial resolution to selectively measure
extracellular glutamate close to synapses (Burmeister & Gerhardt, 2001; Burmeister et
al., 2002b). Another benefit of MEAs over other ex vivo methods is the ability to study
brain regions in vivo without disrupting their extrinsic and intrinsic connections, a
particularly important consideration when examining the complex neural networks of the
hippocampus.
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Chapter 1 Table
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Receptor

Glutamate Regulation

Neuronal activity

IFNβ
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GABA receptors

! Glutamate
receptors, " GABA
receptors
! AMPA receptor
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glutamate receptor
activation
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IL-1 β

IL-1 β receptor

TNFα
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LTP
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receptors

!

NMDA activity

Memory
Cognitive
impairment in
mice lacking gene

Associated diseases
Neuroprotective, used in
treatment of epilepsy

Impairs cognition !Epilepsy!and!neurodegeneration
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memory

Neurodegeneration
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Neurodegeneration

Chemokines

CXCL9, CXCL10, CXCL11

CXCR3

CXCL1, CXCL2

CXCR2

Ccl2

CCR2
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"cAMP
(Important for long
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Memory deficits in
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Pharmacoresistant!epilepsy!

Synaptic excitation

Memory
impairment in
MWM and Water
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Neurodegeneration
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Stroke!and!neurodegeneration

!

!

NMDA activity

Neurodegeneration
Neurodegeneration

Complements
!
C3

CFB

CR1
Major
histocompatibility
complex (MHC)

AMPA expression,
impairs dendritic
morphology

unknown

!

Colocalizes with neurons

Table 1.1. Inflammatory mediators and glutamate homeostasis. Circulating
inflammatory mediators in the CNS produced after PIC-challenge cause changes in
glutamate regulation, neuronal activity, and memory. This table summarizes the changes
resulting from peripheral inflammation.
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Chapter 1 Figures

CA1#

CA3#

EC#
DG#

EC2#
Pyramidal#cell#
Hilar#interneurn#
Mossy#cell#

Granule#cell##

EC3#
EC5#

CA3#
DG#
CA1#

Figure 1.1. Hippocampal schematic. Information enters the hippocampus from different
layers of the entorhinal cortex (EC2, 3, 5) and signals travel through the trisynaptic loop.
Layer 2 projects signals to the granule cells of the dentate gyrus (DG). Signals from the
mossy fiber cells in the DG then progress to the CA3 region and are received in the CA1
via the Shaffer collateral fibers. The CA1 region completes the loop by sending signals to
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layer 5 of the EC. The EC2 and EC3 can also project directly to the CA3 and CA1,
respectively. It should be noted that the CA3 consists of recurrent fibers that can
propagate signals withing the CA3.

Figure 1.2. Diagram of the microelectrode array (MEA). The MEA consists of four
platinum recording sites all of which are mPD plated. Two sites are coated with
glutamate oxidase (1,2- Glu Recording) and the top two sites are coated with an inactive
protein matrix (3,4- Sentinel). When glutamate comes into contact with the recording
sites, it is broken down into alpha-ketoglutarate and the reporter molecule, hydrogen
peroxide. Although sentinel sites allow smaller molecules to pass through the exclusion
layer, larger interferents, such as ascorbic acid and dopamine are blocked. Therefore, we
can subtract the difference between the two sites to determine the concentration of
glutamate without noise or artifact.
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The current research
The aims of the current study were first to characterize glutamate levels in
anesthetized mice after PIC-challenge and second to study the role of glutamate during
KA-induced seizures in awake behaving animals after PIC-challenge. The exact
mechanisms by which peripheral viral infections exacerbate neurodegenerative
conditions is not known, but many major inflammatory mediators generated in response
to peripheral viral challenge have been shown to increase neuronal excitability (Galic et
al., 2012; Hu et al., 2000; Riazi et al., 2015; Viviani et al., 2003) and decrease neuronal
inhibition (Stellwagen et al., 2005; S. Wang et al., 2000), both of which may lead to
increased extracellular glutamate concentrations. These changes in neuronal signaling
may be due to the changes in glutamate receptor expression resulting from a surge of
inflammatory factors as shown in table 1.1. These changes in glutamate homeostasis are
also related to memory impairment and often exacerbate neurodegenerative conditions.
Given recent evidence linking glutamatergic hyperactivity to AD (Bakker et al., 2012;
Busche et al., 2012; Hunsberger, Rudy, et al., 2015; Hunsberger, Weitzner, et al., 2015),
PD (Ahmed et al., 2011; Schapira, 2010), MS (Kostic et al., 2013), and seizures
(Chapman, 2000; Soukupova et al., 2015), deciphering mechanisms by which peripheral
viral infection elevates extracellular glutamate is critical to the prevention of infectionmediated exacerbations in neurodegenerative conditions.
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Chapter 2
Peripherally restricted viral challenge elevates extracellular glutamate and enhances
synaptic transmission in the hippocampus.

Abstract
Peripheral infections increase the propensity and severity of seizures in susceptible
populations. We have previously shown that intraperitoneal (i.p.) injection of a viral
mimic, polyinosinic-polycytidylic acid (PIC), elicits hypersusceptibility of mice to kainic
acid (KA)-induced seizures. The present study was undertaken to determine whether this
seizure hypersusceptibility entails alterations in glutamate signaling. Female C57BL/6
mice were i.p. injected with PIC, and after 24 hours, glutamate homeostasis in the
hippocampus was monitored using the enzyme-based microelectrode arrays. PIC
challenge robustly increased the level of resting extracellular glutamate. While
presynaptic potassium-evoked glutamate release was not affected, glutamate uptake was
profoundly impaired and non-vesicular glutamate release was augmented, indicating
functional alterations of astrocytes. Electrophysiological examination of hippocampal
slices from PIC-challenged mice revealed a several fold increase in the basal synaptic
transmission as compared to control slices. PIC challenge also increased the probability
of presynaptic glutamate release as seen from a reduction of paired-pulse facilitation
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(PPF) and synaptic plasticity as seen from an enhancement of long-term potentiation
(LTP). Altogether, our results implicate a dysregulation of astrocytic glutamate
metabolism and an alteration of excitatory synaptic transmission as the underlying
mechanism for the development of hippocampal hyperexcitability, and consequently
seizure hypersusceptibility following peripheral PIC challenge.
Introduction
Seizures represent a major neuropathological affliction and an important cause of longterm disability. Seizures result from excessive and/or synchronous neuronal activity in
the brain. Cerebral inflammation following trauma, ischemia, infections, tumors, etc., has
been recognized as an important pathological feature that predisposes and/or elicits
seizures (Marchi et al. 2009; Vezzani and Granata 2005; Ravizza et al. 2011). The
underlying mechanisms entail the activation of resident innate immune cells, chiefly
microglia and astrocytes, as well as the recruitment and activation of peripheral
leukocytes leading to the production of a plethora of cytokines, chemokines,
prostaglandins and other inflammatory agents. These inflammatory agents may increase
excitatory inputs, decrease inhibitory inputs, or both, resulting in hyperexcitability of the
neuronal networks, a hallmark of seizures.

Notably, also peripheral inflammation can increase seizure propensity in susceptible
individuals (Tellez-Zenteno et al. 2005; Scheid and Teich 2007; Verrotti et al. 2009). The
underlying mechanisms involve relaying peripheral innate immunity signals to the brain
whereby they induce a “mirror inflammation” (Dantzer and Kelley 2007; Dantzer et al.
2008; Quan and Banks 2007). Several experimental studies dovetail with these clinical
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data. For example, the simulation of bacterial infection via intraperitoneal (i.p.) injection
of a bacterial endotoxin, lipopolysaccharide (LPS) increases seizure susceptibility in mice
as seen from a decrease in the threshold of clonic seizures instigated by
pentylenetetrazole (PTZ) (Sayyah et al. 2003). In a rat model of inflammatory bowel
diseases, intracolonical injection of 2,4,6-trinitrobenzene sulfonic acid (TNBS) increases
the susceptibility to PTZ-induced seizures (Riazi et al. 2008). Moreover, experimental
arthritis and subcutaneous granuloma decrease the onset and increase the score of PTZevoked seizures (Rao et al. 2008).

We have also shown that peripheral viral challenge robustly increases seizure
susceptibility (Kirschman et al. 2011; Michalovicz and Konat 2014). In this experimental
paradigm, intraperitoneal injection of a viral mimetic, polyinosinic-polycytidylic acid
(PIC) results in a several-fold increase in the extent and duration of status epilepticus
induced by kainic acid (KA) in mice (Kirschman et al. 2011). This seizure
hypersusceptibility is protracted for three days after PIC challenge (Michalovicz and
Konat 2014). Of note, PIC is an unstable inflammagen that is rapidly degraded in the
bodily fluids (Krasowska-Zoladek et al. 2007), and when injected intraperitoneally does
not reach the circulation (Fil et al. 2011). Therefore, PIC challenge represents a bolus
stimulation of the innate immune cells within the peritoneal cavity, and these
peripherally-generated inflammatory mediators instigate a cerebral response (Konat
2015). In particular, PIC challenge triggers a robust but transient surge of blood
cytokines, i.e., interferon β (IFNβ), interleukin 1β (IL-1β), IL-6 and tumor necrosis factor
α (TNFα) (Michalovicz and Konat 2014; Cunningham et al. 2007). This cytokine surge
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instigates a global cerebral response as seen from the upregulation of a myriad of
inflammatory genes in all major brain regions (Cunningham et al. 2007; Konat et al.
2009; Fil et al. 2011). In the hippocampus, the ictal site of KA-induced seizures (Ben-Ari
and Cossart 2000), PIC challenge dysregulates the expression of over six hundred genes
that, in addition to inflammatory and stress proteins, encode several neurotransmissionrelated proteins and microRNAs (Michalovicz and Konat 2014;Michalovicz et al. 2015).
This genomic reprograming undoubtedly underlies the development of seizure
hypersusceptibility, albeit specific cellular and molecular pathways have not been
defined.

The present study was undertaken to test the hypothesis that hyperexcitability ensuing
PIC challenge features dysregulation of glutamate homeostasis. We employed the
enzyme-based microelectrode technology for in vivo monitoring of extracellular
glutamate levels in the hippocampus to identify neurotransmission-associated events
affected by PIC challenge. The characterization of glutamate homeostasis was
complemented with an electrophysiological study assessing synaptic transmission and
plasticity in acute hippocampal slices.

Materials & Methods
Animals
Eleven-week-old C57BL/6 female mice obtained from Charles River (Wilmington, MA)
were group housed with free access to food and water in a temperature and humiditycontrolled colony room with a 12:12 light/dark cycle. Female mice were used to provide
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compatibility with previous studies (Cunningham et al. 2007; Fil et al. 2011; Konat et al.
2009; Michalovicz and Konat 2014). Acute antiviral response was induced by i.p.
injection of 12 mg/kg of PIC (Invivogen, San Diego, CA) in saline. Mice injected with
100 µL of saline served as vehicle controls. Mice were examined 24 h after PIC or saline
injection. The West Virginia University and Auburn University Animal Care and Use
Committees approved all experimental procedures.
In vivo glutamate measurement
Changes in extracellular glutamate in the hippocampus were monitored using the
microelectrode arrays (MEA) technique (Burmeister and Gerhardt 2001) as previously
described (Hunsberger et al. 2015a; Hunsberger et al. 2015b). Briefly, the electrodes
obtained from Quanteon (Nicholasville, KY) were coated with glutamate oxidase and
calibrated, as exemplified in Figure 2.1. A glass micropipette (Quanteon) was mounted to
the arrays for intracranial drug delivery. Mice were anesthetized with isoflurane (1-4%
continuous inhalation), placed in a stereotaxic device (David Kopf Instruments, Tujunga,
CA) and the MEA/micropipette assemblies were inserted into the hippocampal subregions, i.e., dentate gyrus (DG), cornu ammonis 1 (CA1) and cornu ammonis 3 (CA3).
The stereotaxic coordinates from the bregma were AP: -2.3 mm, ML: +/-1.5 mm, DV:
2.1 mm for DG, AP: -2.3 mm, ML: +/-2.7 mm, DV: 2.25 mm for CA3 and AP: -2.3 mm,
ML: +/-1.7 mm, DV: 1.4 mm for CA1. A reference electrode was implanted under the
skin in a remote site. All MEA recordings were performed at 10 Hz using constantpotential amperometry. All measurements and injections were performed after a stable
baseline was reached (20-45 min). Both hemispheres were used for drug injection, and
sub-regions within a hemisphere, were counterbalanced.
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Tonic glutamate levels were calculated in all three sub-regions by averaging extracellular
glutamate levels over 10-s periods. Evoked release was induced in a subset of animals by
delivering 50-100 nL of 70 mM of potassium chloride (KCl) solution every 2-3 min. The
amplitudes of ten reproducible signals were averaged and compared. To measure
glutamate uptake, a subset of animals received 1-2 injections at 50 nL increments within
a 50-250 nL range of 200 µM glutamate (Sigma-Aldrich, St. Louis, MO) delivered every
2-3 minutes in one hemisphere. Temporal clearance of glutamate was monitored and
expressed as the net area under the curve (AUC). Glutamate release in a subset of animals
was measured in the opposite hemisphere following inhibition of glutamate uptake with
50-250 nL of 500 µM DL-threo-β-benzyloxyaspartate (TBOA; Tocris, Ellisville, MO).
The amperometric data were analyzed using a custom Microsoft Excel software program
(MatLab) as previously described (Hunsberger et al. 2015a; Hunsberger et al. 2015b).
Data from some hippocampal regions were excluded for reasons including failure of the
MEA or clogging of the micropipette. The number of mice per treatment group for
glutamate measurements is indicated in Table 2.1.
Hippocampal slice preparation
Animals were euthanized with carbon dioxide, the hippocampi were isolated and 350-µm
thick transverse slices were prepared using a Leica VT1200S Vibratome (Leica
Microsystems, Wetzlar, Germany). Slices were incubated at room temperature in
artificial cerebrospinal fluid (ACSF; 124 mM NaCl, 3 mM KCl, 1.2 mM MgSO4, 2.1 mM
CaCl2, 1.4 mM Na2 PO4, 26 mM NaHCO3, 20 mM dextrose, pH 7.4) saturated with 95%

27

O2/5% CO2. After one-hour incubation, slices were transferred into a recording chamber
for electrophysiological measurements as previously described (Wang & Zheng 2015).
Extracellular field potential recording
The slices were examined) with an Olympus BX50WI microscope equipped with a highresolution, high-sensitivity CCD camera (Dage-MTI, Michigan City, IN). A bipolar
stimulating electrode (100-µm separation, FHC, Bowdoinham, ME) was placed in the
Schaffer collateral pathway. A patch pipette drawn with the P87 Brown-Flaming Puller,
(Sutter Instruments, Novato, CA) and filled with ACSF (2-5 MΩ, 1.5 mm OD, 0.86 mm
ID) was placed in the stratum radiatum of CA1 to record field excitatory postsynaptic
potentials (fEPSPs). All parameters, including pulse duration, width, and frequency were
computer controlled. Constant-current pulse intensities were controlled by a stimulus
isolation unit A360 (WPI, Sarasota, FL).

Basal synaptic transmission, represented by input-output responses, was determined as
ratios of the slopes of fEPSP and plotted as a function of stimulus intensities. For paired
pulse facilitation (PPF), pairs of stimuli separated by varying intervals between them
were delivered to the stratum radiatum at 0.05 Hz. Paired responses were averaged, and
ratios of fEPSP slopes from the second stimulus (fESPS2) to fEPSP slopes from the first
stimulus (fESPS1) were calculated and plotted as a function of interstimulus intervals.
Long-term potentiation (LTP) was evaluated after 10 min of stable baseline period. Initial
recordings were carried out with low frequency stimulation (0.05Hz) at intensities of 0500 µA to determine the maximal excitatory potential. For LTP experiments the stimulus
intensity was adjusted to produce 50% of the amplitude at which initial population spikes
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begin to appear. LTP was induced with 5 high frequency stimuli (HFS; 100 pulses,
100Hz) every 20 seconds. LTP was measured 55-60 minutes post HFS.

The data were recorded online using the WinLTP 2.2 software (University of Bristol,
UK). Standard off-line analyses of the data were conducted using Prism software
(GraphPad Prism version 5.00, San Diego California, USA). Results are expressed as
means ± SEMs.
Statistical analyses. Results were evaluated by the one-way ANOVA using JMP (SAS,
Cary, NC) and SPSS v.21 (SPSS Inc., Chicago, IL) for glutamate and
electrophysiological data, respectively. For electrophysiological data, significant omnibus
tests were followed by Student’s t-tests. Results are presented as means ± SEMs, and
differences between groups were considered statistically significant at p ≤ 0.05.
Results
An increased glutamatergic transmission is a plausible mechanism underscoring PICinduced hypersusceptibility to KA-induced seizures found in previous studies
(Kirschman et al. 2011; Michalovicz and Konat 2014). Here, we assessed glutamate
homeostasis in the hippocampus, the ictal site of KA-induced seizures (Ben-Ari and
Cossart 2000), using enzyme-based microelectrode technology that allows real-time
monitoring of extracellular glutamate in vivo. We used isoflurane to avoid anestheticinduced changes in resting glutamate levels (Mattinson et al. 2011), and measured
glutamate in hippocampal subregions known to be rich in glutamate receptors, i.e., DG,
CA1 and CA3 (Nimchinsky et al. 2004;Pettit and Augustine 2000). All measurements
were performed 24 h after i.p. injection of PIC or saline. As shown in Fig. 2.2a, PIC29

challenge induced a robust increase in tonic, resting glutamate levels in all three subregions. The highest increase of 11-fold over control was observed in DG [F(1,18) =
41.49, p < .0001]. CA1 [F(1,19) = 15.58, p = .0009] and CA3 [F(1,18) = 18.94, p =
.0004] featured 9.8-fold and 5.8-fold increase, respectively.

Several mechanisms can be considered to account for the increase of tonic glutamate. For
example, PIC challenge may alter the capacity or “ceiling” of neuronal terminals to
release glutamate (Hinzman et al. 2010). To test this possibility, we used the paradigm of
potassium-evoked glutamate release (Day et al. 2006). As shown in Fig. 2.2b, the
injection of KCl induced a transient (approximately 5 s) elevation of extracellular
glutamate. No differences were observed between PIC-challenged vs. control mice in any
sub-region (DG [F(1,7) = .11, p = .75]; CA1 [F(1,7) = .002, p = .96]; CA3 [F(1,7) = .04,
p = .84]; Fig. 2c). These results indicate that PIC challenge does not increase the
neurotransmitter content in presynaptic terminals.

A decreased glutamate clearance represents an alternative mechanism for the rise of
extracellular glutamate. To test this option, we injected exogenous glutamate, and
monitored its clearance by measuring net AUC. We first compared the amplitude of
glutamate signals following injection of exogenous glutamate to confirm differences in
net AUC between the PIC-challenged and saline-injected mice following application of
exogenous glutamate were due to alterations in the uptake and not to differences in the
amount of applied glutamate (Hunsberger et al. 2015a; Hunsberger et al. 2015b). Prior to
AUC measurement, maximal amplitudes of the glutamate signal were determined to
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ensure reproducibility of glutamate injection. Fig. 2.3a shows no significant differences
in the maximal amplitudes in any sub-region in control vs. PIC-challenged mice (DG
[F(1,9) = .06, p = .81]; CA1 [F(1,7) = .25, p = .63]; CA3 [F(1,9) = .43, p = .53]). Also, no
effect of PIC challenge on the diffusion of exogenous glutamate within the tissue
expressed as the Trise values, i.e., the time for the signal to reach maximum amplitude
(Sykova et al. 1998), was evident in any sub-region (DG [F(1,9) = .07, p = .80]; CA1
[F(1,7) = .25, p = .63]; CA3 [F(1,9) = .24, p = .63]; Fig. 2.3b), suggesting any reductions
in glutamate uptake were not because of diffusion from the point source (micropipette) to
the MEA. Temporal analysis of glutamate levels following its injection revealed a
profoundly delayed clearance profile in PIC-challenged mice (Fig. 2.3c), indicative of an
impairment of the neurotransmitter’s uptake. The quantitation of this impairment is
shown in Fig. 2.3d. The greatest increase in net AUC induced by PIC challenge of 8.3fold over control was found in CA3 [F(1,9) = 11.55, p = .008]. The values for DG [F(1,9)
= 13.77, p = .005] and CA1 [F(1,7) = 18.16, p = .004] were 6.7-fold and 3.8-fold,
respectively.

The augmentation of tonic glutamate may also result from an increased release of
glutamate by astrocytes. We inhibited glutamate uptake with TBOA, a competitive nontransportable EAAT blocker (Shimamoto et al. 1998; Montiel et al. 2005; Tovar et al.
2009) to confirm the involvement of these receptors and to unmask the release of
glutamate (Jabaudon et al. 1999). Local application of TBOA produced a transient
increase in the extracellular glutamate concentration in both PIC-challenged and control
mice (Fig. 2.4a), although the amplitude of this increase differed (Fig. 2.4b). Thus, DG
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[F(1,8) = 5.80, p = .04] and CA1 [F(1,8) = 7.06, p = .03] featured an 18- and 17-fold
increase in PIC-challenged vs. control mice. In contrast, PIC challenge had no effect on
glutamate release in CA3 [F(1,8) = .51, p = .50].

The increased tonic glutamate, the impaired glutamate uptake, and the increased
glutamate release implicated that PIC challenge might enhance glutamatergic
neurotransmission in the hippocampus. To verify this notion, we examined basal synaptic
transmission and synaptic plasticity in hippocampal slices by field recordings. Fig. 2.5a
shows representative traces of EPSPs in hippocampi from PIC challenged vs. control
mice. PIC challenge markedly increased the amplitude and slope of the EPSP. As seen
from Fig. 2.5b, PIC challenge profoundly enhanced basal synaptic transmission denoted
by input-output responses of the neuronal networks (stimulus response curve)
[F(1,41)=30.35, p<0.0001], at each point of measurement [ps>.05]. Throughout the range
of stimulus intensities from 50 to 500 µA, the synaptic efficiency increased by over 2.5fold in slices from PIC-challenged mice as compared to slices from saline-injected mice.
A change in basal synaptic transmission may result from alterations in pre- post- and
peri-synaptic elements. To further characterize which component across the synapse
actually contributed to PIC-induced increased synaptic transmission, we used the PPF
protocol that reflects residual calcium levels, a presynaptic mechanism that plays a major
role in short-term and long-term plasticity. PIC challenge decreased PPF [F(1,19)=7.391,
p=0.014] at the short (50 ms) stimulus interval [p<.05], indicating an increase in
presynaptic release probability due to alteration in either presynaptic compartment or
astrocyte calcium signaling (Fig. 2.5c). Albeit, no effect was observed at longer intervals
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[ps>.0.5]. LTP, a cellular substrate of plasticity that may feature both pre- and postsynaptic expression (Padamsey and Emptage 2014), was significantly increased by PIC
challenge [F(1,68)=2.47, p=.0007; Fig. 2.5d].

Discussion
The major finding of our study is that peripheral PIC challenge disrupts cerebral
glutamate homeostasis, resulting in a robust increase in the basal extracellular glutamate
concentration (Fig. 2.2a). This increase is likely to underlie hippocampal
hypersusceptibility to KA-induced seizures in PIC challenged mice (Kirschman et al.
2011; Michalovicz and Konat 2014). In support of this notion, increased tonic glutamate
levels have been shown to correlate positively with the severity of focal motor seizures
induced by intrahippocampal injection of 4-aminopyridine (4-AP) (Stephens et al. 2014).
Also, astrocytic release of glutamate has been shown to facilitate the initiation of seizures
(Kang et al. 2005), while the suppression of glial glutamate release leads to decreased
seizure susceptibility (De Bundel D. et al. 2011). In addition, human epileptogenic
hippocampi exhibit augmented basal glutamate levels during interictal periods that may
contribute to seizure generation (Cavus et al. 2005). Moreover, the overflow of
extracellular glutamate has been recognized as a key factor in the development of
neuronal hyperexcitability (Featherstone and Shippy 2008). For example, dysregulation
of extracellular glutamate homeostasis has been directly linked to hyperexcitability of
cortical and spinal cord neurons at diverse pathological conditions (Campbell et al. 2012;
Campbell et al. 2014; Campbell and Hablitz 2004; Campbell and Hablitz 2008;
Putatunda et al. 2014). Glutamate-induced hyperexcitability is chiefly mediated by
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ionotropic glutamate receptors, in particular, NMDA receptors, but the involvement of
metabotropic glutamate receptors has also been implicated (Featherstone and Shippy
2008). The mechanism entails a direct ligation of the receptors, although other, more
circuitous pathways may also be involved. Consequently, we posit that the amplified
response of the CA1 pyramidal cells induced by the upsurge of extracellular glutamate in
PIC challenged mice contributed to the enhanced synaptic transmission (Fig. 2.5b), PPF
(Fig. 2.5c), and LTP (Fig. 2.5d). However, a possibility that PIC challenge might also
reduce inhibitory signaling can be considered. For example, a reduction in the number of
inhibitory synapses was observed in the cortex of mice following repeated LPS injections
(Chen et al. 2014).
The elevation of tonic glutamate could be due to increased glutamate release, decreased
glutamate uptake, or both. Local application of potassium evoked the same amounts of
glutamate in PIC and control hippocampi (Fig. 2.2c), indicating no alteration in the
capacity or ceiling of presynaptic release of this neurotransmitter. However, the clearance
of injected glutamate was profoundly hampered (Fig. 2.3d), indicating an impairment of
glutamate uptake by PIC challenge. Inflammatory cytokines upregulated in the
hippocampus in response to PIC challenge might mediate this impairment. For example,
IL-1β and TNFα inhibit astrocytic glutamate uptake (Hu et al. 2000; Ye and Sontheimer
1996), and the Tnfa and Il1b gene expression is upregulated in the hippocampi of PICchallenged mice as compared to controls (Michalovicz and Konat 2014).
The excitatory amino acid transporters 1 and 2 (EAAT1/2) expressed almost exclusively
in astrocytes play the major role in the uptake of glutamate (Niciu et al. 2012). The
application of TBOA, a specific competitive inhibitor of EAAT1/2 (Shimamoto et al.
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1998), induced a transient increase of extracellular glutamate (Fig. 2.4), indicating the
involvement of these transporters. However, the contribution of neuronal transporters
cannot be ruled out. Moreover, in DG and CA1 of PIC challenged animals, local TBOA
application elicited much greater glutamate spikes than in control tissues. Because
blocking of EAAT unmasks glutamate release (Jabaudon et al. 1999), our results suggest
that PIC challenge not only impairs glutamate uptake but also augments glutamate release
from astrocytes. This result is consistent with previous studies showing the enhancement
of astrocytic glutamate release by inflammatory mediators, i.e., IL-1β (Casamenti et al.
1999), TNFα and prostaglandins (Bezzi et al. 2001). Altogether, our results strongly
implicate astrocytes as cellular targets for inflammatory mediators generated in response
to PIC challenge.
In contrast to DG and CA1, no difference between PIC challenged and control mice in
the post-TBOA glutamate amplitude was detectable in CA3 (Fig. 2.4), suggesting that the
release of glutamate in this subregion is not affected by the inflammatory milieu
instigated by PIC challenge. Because presynaptic glutamate release was not altered in
CA3 (Fig. 2.2c), the astrocytic release mechanisms are likely candidates to account for
this region-specificity. Astrocytes release glutamate through different mechanisms, e.g.,
Ca2+-dependent exocytosis, glutamate exchange via the cystine–glutamate antiporter (Xc) and reversal of uptake by glutamate transporters (Malarkey and Parpura 2008). It is
tempting to speculate that unlike DG and CA1 astrocytes, CA3 astrocytes use
mechanisms that are not susceptible to the inflammatory milieu induced by PIC
challenge. Such a differential response is buttressed by a previous observation that in the
presence of TBOA, tetraethylammonium chloride elicits a several-fold greater glutamate
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release in CA3 than in CA1 or DG (Chiba et al, 2010). However, specific mechanisms
may vary between these two paradigms.
Field recordings in hippocampal slices prepared from PIC-challenged vs. control mice are
congruent with the dysregulated glutamate homeostasis observed in vivo. Thus, the robust
increase in the basal glutamatergic synaptic transmission (Fig. 2.5b) likely resulted from
the elevation of extracellular glutamate (Fig. 2.2a). The underlying mechanisms might
involve the activation of extrasynaptic glutamate receptors (Petralia 2012). PPF, an index
of short-term plasticity, reflects synaptic efficacy determined by the probability of
presynaptic neurotransmitter release (Zucker and Regehr 2002). PIC challenge
significantly reduced PPF (Fig. 2.5c), indicating that increased probability of glutamate
release at the terminals of the Schaffer collaterals might contribute to the increased
synaptic transmission. However, this increased presynaptic activity is in divergence with
unchanged potassium-evoked glutamate amplitudes (Fig. 2.2c), another facet of the
presynaptic neurotransmitter release. A plausible explanation is that the glutamate
amplitudes measure the maximum capacity for release by depleting presynaptic
glutamate pool with large doses of potassium, and these measurements may not be
compatible with the physiological/functional release measured by PPF. Furthermore, LTP
that can be expressed at postsynaptic as well as presynaptic loci (Padamsey and Emptage
2014) was increased by PIC challenge (Fig. 2.5d), indicating an enhancement of synaptic
strength. Altogether, these results show that PIC challenge increases both basal synaptic
transmission and synaptic plasticity.
In addition, the slice experiments provide compelling evidence for the intrinsic nature of
the hippocampal alterations induced in PIC-challenged mice. For instance, peripheral
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inflammation might have increased the permeability of KA and/or glutamate through the
blood-brain barrier (BBB), leading to hyperexcitability of hippocampal networks that
would manifest as seizure hypersusceptibility. However, the robustly augmented
excitatory synaptic transmission in the perfused slices from PIC-challenged as compared
to control animals shows that the hyperexcitability indeed originates in the hippocampal
parenchyma. This finding corroborates our previous study showing greatly increased
spontaneous ictal activity elicited with 4-aminopurine in hippocampal slices from PICchallenged vs. control mice (Konat et al. 2012). As discussed above the augmentation of
synaptic transmission results from the elevation of extracellular glutamate. Ergo, the slice
studies also indirectly verify the intrinsic nature of glutamate dysregulation observed in
vivo.
We have recently shown that PIC challenge profoundly upregulates expression of the
complement in the hippocampus, and that this upregulation is commensurate with the
period of seizure hypersusceptibility (Michalovicz et al. 2015). The complement is a
major mediator of synaptic modifications (Stevens et al. 2007; Schafer et al. 2012;
Stephan et al. 2013), and complement proteins have proconvulsive activity when injected
into the hippocampus (Xiong et al. 2003). Therefore, it’s tempting to speculate that the
alteration of glutamate homeostasis and hyperexcitability might be induced by the
complement proteins. The mechanisms of such alterations might entail anaphylatoxins
generated through the complement activation. Anaphylatoxins can activate their cognate
receptors on microglia, astrocytes and neurons resulting in the generation of
inflammatory factors that affect function of the postsynaptic terminals. For example, Il1β (Viviani et al. 2003; Yang et al. 2005), IL-6 (Xiaoqin et al. 2005; Samland et al.
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2003), TNFα (Beattie et al. 2002; Stellwagen et al. 2005), IFNβ (Hadjilambreva et al.
2005), CXCL10 (Ragozzino et al. 1998), CXCL1/2 (Giovannelli et al. 1998; Ragozzino
et al. 1998) and the prostaglandin PGE2 (Chen and Bazan 2005) can enhance
glutamatergic synaptic transmission. Thus, in addition to the disruption of glutamate
homeostasis discussed formerly, inflammatory factors may induce hyperexcitability of
the hippocampal neurons. Alternatively, complement proteins or their
derivatives/complexes might bind to synaptic structures resulting in functional
impairment of surface receptors that control glutamate homeostasis and/or synaptic
transmission.
Recently, seizure hypersusceptibility of rats subjected to colonic inflammation (Riazi et
al. 2008) has been linked to an increased synaptic transmission in the hippocampus (Riazi
et al. 2015), albeit the extent of this increase was much less than the increase observed
here. In contrast to our study, the colonic inflammation reduced LTP in hippocampal
slices. Therefore, it seems that hippocampal hyperexcitability may be a common
mechanism by which peripheral inflammation increases seizure susceptibility, but the
effects on synaptic plasticity vary depending on the inflammatory paradigm.
In conclusion, our results indicate that inflammation instigated by peripheral PIC
challenge enhances excitatory synaptic transmission and plasticity in the hippocampus by
elevating extracellular glutamate concentration and increasing presynaptic activity. These
putative pathway are likely responsible for the development of seizure
hypersusceptibility. Our results warrant a comprehensive investigation of the underlying
mechanisms at both the cellular and molecular level to provide a foundation for the
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development of therapeutic strategies for the management of inflammation-related
seizures.
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Chapter 2 Table
DG

CA3

CA1

PIC

Saline

PIC

Saline

PIC

Saline

Tonic

11

9

11

9

12

9

KCl

5

4

5

4

5

4

5

6

6

5

4

5

6

4

6

4

6

4

Exogenous
glutamate
TBOA

Table 2.1. Number of mice used in glutamate measurement experiments.
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Chapter 2 Figures

Figure 2.1. In vitro calibration of a self-referencing microelectrode measuring the change
in current (pA) on a glutamate oxidase site (GluOx; red) vs. a sentinel site (Sent; blue).
Interferents, such as ascorbic acid (AA) and dopamine (DA), did not alter the current at
either glutamate oxidase or sentinel sites. Addition of glutamate (Glu) produced a
stepwise current increase on the glutamate oxidase site, but no change on the sentinel site.
Hydrogen peroxide (H2O2) produced an increase in current on both sites. Sensitivity,
slope, limit of detection, and R2 values were calculated after calibration.
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Figure 2.2. Tonic glutamate levels and evoked glutamate release in the hippocampus.
Mice were intraperitoneally injected with PIC or saline (control). After 24 h,
hippocampal glutamate was analyzed by the enzyme based microelectrode technique in
the dentate gyrus (DG), cornu ammonis 1 (CA1) and cornu ammonis 3 (CA3). (a)
Extracellular tonic glutamate levels in the hippocampal sub-regions. (b) Baseline-
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matched representative traces of K+ evoked release of glutamate in CA3.

(c) The

amplitudes of K+ evoked release of glutamate in the hippocampal sub-regions. For details
see Methods. Bars represent means ± SEMs. Asterisks denote values significantly
different from respective controls ***p≤ .001, ****p≤ .0001).
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Figure 2.3. The uptake of exogenous glutamate in the hippocampus. Mice were
intraperitoneally injected with PIC or saline (control). After 24 h, hippocampal glutamate
was analyzed by the enzyme based microelectrode technique in different hippocampal
sub-regions as indicated. (a) The amplitude of signals following local injection of 200
µM glutamate. (b) Glutamate diffusion expressed as time to reach maximum amplitude
(Trise). (c) Peak-matched representative traces in the DG. (d) Glutamate uptake expressed
as the net area under the curve (AUC). For details see Methods. Bars represent
means ± SEM. Asterisks denote significant differences from respective controls
(**p≤ .01).
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Figure 2.4. Spontaneous release of extracellular glutamate in the hippocampus. Mice
were i.p. injected with 12 mg/kg of PIC or saline (control). After 24 h, glutamate uptake
was blocked by the application of 500 µM TBOA to unmask glutamate release, and the
levels of extracellular glutamate were determined in different hippocampal sub-regions as
indicated. (a) A representative trace of transient glutamate release in DG in PIC- and
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saline-injected mice. (b) The amplitude of extracellular glutamate in the hippocampal
sub-regions following TBOA application. For details see Methods. Bars represent
means ± SEM. Asterisks denote significant differences from respective controls (*p≤ .05).
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Figure 2.5. Synaptic transmission in hippocampal slices. Mice were intraperitoneally
injected with PIC or saline (control), and after 24 h, hippocampal slices were prepared.
The Schaffer collateral pathways of CA3 were stimulated, and fEPSPs evoked in the
striatum radiatum of CA1 were recorded. (a) Representative traces of fEPSPs evoked at a
stimulus intensity of 200µA. (b) Basic synaptic transmission as the fEPSP slope
measured at increasing stimulus intensity (c) Paired-pulse facilitation expressed as the
change of ratios of the second stimulus fEPSP slopes to the first stimulus fEPSP slopes
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plotted as a function of interstimulus intervals. (d) Long term potentiation calculated as
the fEPSP ratio over time. Inset: Representative traces shown include data collected from
saline-injected and PIC-challenged animals during baseline recordings (black) overlayed
on traces during 55-60 minute LTP (brown). For details see Methods. Symbols represent
means ± SEMs from 3 mice (12 slices) per group. Asterisks denote significant differences
from respective controls (Student’s t-test; * p≤ .05, ***p≤ .001).
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Chapter 3

Antiviral acute phase response increases tonic glutamate levels and seizure severity
Abstract
Cerebral inflammation, resulting from peripheral bacterial and viral infection, is
associated with epilepsy and other neurodegenerative conditions. Recent evidence reveals
that intraperitoneal (i.p.) injection of a viral mimic, polyinosinic-polycytidylic acid (PIC),
elicits a profound increase in kainic acid (KA)-induced seizure susceptibility compared to
saline-treated controls. We have previously shown that systemic injection of PIC results
in a robust increase in tonic glutamate levels in anesthetized mice most likely due to a
decrease in glutamate clearance. The current study was undertaken to determine the
relationship between PIC challenge and glutamate homeostasis in awake, behaving mice.
Because the hippocampus is the ictal site for KA-induced seizures, we implanted
microelectrode arrays into the CA1 of the hippocampus to record tonic and transient
glutamate levels. Our results revealed an increase in tonic glutamate levels following PIC
challenge, which gradually declined over four days. Tonic glutamate levels were also
predictive of KA-induced seizure severity, as indicated by an increase in the average and
cumulative seizure scores. These results implicate that the elevation of glutamate by PIC
challenge is likely to underlie enhanced seizure susceptibility.
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Introduction
Peripheral inflammation is a primary factor in the pathophysiology of seizures
and development of epilepsy (Vezzani & Granata, 2005). Moreover, individuals with
cerebral inflammation, resulting from infection or trauma, are often more prone to
seizures (Tellez-Zenteno, Matijevic, & Wiebe, 2005). Seizures are characterized by
abnormal neuronal firing most likely resulting from an increase in excitatory glutamate
neurotransmission and decrease in GABA inhibitory neurotransmission (Rowley, Martin,
& Marsden, 1995). Although the molecular mechanisms underlying seizure onset and
severity are not well understood, recent evidence suggests that inflammatory mediators,
in response to peripheral inflammation, can cause neuronal and glial changes in the
central nervous system (CNS) (Marchi et al., 2009; Viviani et al., 2003; Wang, Q. Cheng,
S. Malik, & J. Yang, 2000; S. Wang et al., 2000; Wilkinson, Mathieson, & Pittman,
1993). These changes may shift the balance between excitation and inhibition towards
neuronal hyperexcitability.
To study the cerebral effects of peripheral inflammation, polyinosinicpolycytidylic acid (PIC), a viral mimetic, is often injected i.p. the acute phase response
(APR) (Cunningham et al., 2007). The APR results in the generation of type 1 interferons
and other inflammatory factors (Muller et al., 1994) that are produced in the periphery
and relayed to the brain. PIC-challenge in rodents results in sickness behavior
(Cunningham et al., 2007) and an upregulation of cytokine, chemokine, and complement
genes in the CNS (Fil et al., 2011; G. W. Konat et al., 2009; Michalovicz & Konat, 2014;
Michalovicz et al., 2015). These changes peak between 3 and 6 hours, and in some cases,
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are observed for up to 3 days post PIC injection (Fil et al., 2011; G. W. Konat et al.,
2009; Michalovicz & Konat, 2014; Michalovicz et al., 2015).
Though alterations in neural networks, and the resulting sickness behavior, serve
to protect the host, a growing body of evidence suggests these modifications may have
deleterious effects in the presence of other neuropathological conditions. For example,
viral infections in the periphery can exacerbate neurodegenerative conditions, including
Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, and
seizures in humans (see Perry et al., 2003 for review). Previous work shows that PICchallenged mice exhibit an increase in the extent and duration of kainic acid (KA)induced seizures (Kirschman et al., 2011). This seizure hypersusceptibility is protracted
for 3 days (Michalovicz & Konat, 2014). Our recent work suggests that glutamate, the
primary excitatory neurotransmitter, may mediate the seizure hypersusceptibility
observed after PIC insult as seen from an increase in tonic glutamate levels in the
hippocampal subregions of anesthetized PIC-challenged mice compared to saline-treated
controls (Hunsberger et al., 2016). In addition, recent studies examining the effects of
aging on seizure severity and glutamate homeostasis in rats revealed a strong association
between pre-seizure tonic (resting) glutamate levels in the CA1 of the hippocampus and
seizure intensity (Stephens et al., 2014). Notably, pre-seizure tonic glutamate levels were
also predictive of glutamate transient amplitude during seizure in these animals.
Glutamate transients are spontaneous bursts of glutamate that until recently were
not detectable with previous recording techniques (i.e., microdialysis) (Hascup et al.,
2011). The need to monitor the fast temporal dynamics of glutamate neurotransmission
has been recognized and achieved by the development of the microelectrode array (MEA)
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technology (Burmeister et al., 2002a; Hascup et al., 2011). To determine the relationship
between peripheral inflammation, seizure susceptibility, and glutamate homeostasis, we
employed the MEA technology in awake-behaving mice. Because the hippocampus is the
primary site of ictal onset instigated by KA injection (Ben-Ari & Cossart, 2000) and
cerebral changes are observed for up to 3 days following PIC injection (Michalovicz &
Konat, 2014), seizures were induced and glutamate measured for four days in the CA1 of
the hippocampus of PIC-challenged mice. The CA1 was chosen based on our previous
studies

revealing

robust

changes

in

glutamate

homeostasis

and

synaptic

neurotransmission in this region (Hunsberger et al., 2016).
Materials & Methods
Animals. Eight-week-old female mice of a C57BL/6 background strain obtained
from Jackson labs (Bar Harbor, ME) were group housed with free access to food and
water in a temperature- and humidity-controlled colony room with a 12:12 light/dark
cycle. Female mice were used to provide compatibility with previous studies,
(Cunningham et al., 2007; Fil et al., 2011; Hunsberger et al., 2016; G. W. Konat et al.,
2009; Michalovicz & Konat, 2014). Mice were weighed daily for the duration of the
study. The West Virginia University and Auburn University Animal Care and Use
Committees approved all experimental procedures.
MEA preparation. Self-referencing, ceramic-based MEAs were assembled and
prepared for in vivo recordings as previously described (Burmeister, Moxon, & Gerhardt,
2000; Burmeister et al., 2002a). Briefly, MEAs obtained from Quanteon (Nicholasville,
KY, USA) were coated with glutamate oxidase (recording sites) and nonactive protein,
1% BSA/glutaraldehyde (sentinel sites), for self-referenced comparison. Prior to use,
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MEAs were calibrated as previously described (Hunsberger, Rudy, et al., 2015;
Hunsberger et al., 2016; Hunsberger, Weitzner, et al., 2015) and modified for freelymoving recordings in awake animals. To modify the MEAs, the MEA paddle was
shortened and attached to a miniature omnetics connector (Omnetics Connector
Corporation; Minneapolis, MN) to create a pedestal connected by copper wires. Copper
wires were prepared by stripping the ends and soldering one end to the gold-plated pin on
the omnetics connector and the other to one of the four sites on the MEA paddle. To
secure the paddle to the omnetics connector and ensure that moisture did not penetrate the
pedestal, waterproof epoxy was applied, and the copper wires were tucked around the
connector (Rutherford, Pomerleau, Huettl, Stromberg, & Gerhardt, 2007; Stephens et al.,
2014). The completed pedestal was allowed to dry for at least 24 hours. An Ag/Cl
reference electrode was also prepared and soldered to a gold-plated pin.
Electrode Implantation. On Day 1 of the experiment, mice were anesthetized
with isoflurane (1-4% inhalation; continuous), placed into a stereotaxic device (Stoelting,
Wood Dale IL, USA), and a glutamate-selective MEA pedestal was implanted into either
the right or left hemisphere of the CA1 (AP: -2.3 mm, ML: +/-1.7 mm, DV: 1.4 mm)
based on stereotaxic coordinates (Paxinos & Franklin, 2012). Three small holes were
drilled in the skull, two of which were used for a stainless steel screw to serve as an
anchor, and the third hole used for placement of the reference electrode. The assembly
was then secured with four layers of acrylic resin (Lang Dental, Wheeling IL, USA).
After surgery, mice were placed on a heating pad to help maintain body temperature until
recovered from anesthesia. Injection of bupivicaine (1-2 mg/kg) was given immediately
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after surgery to alleviate pain. Fluids containing ketoprofen (2-5 mg/kg) were given as
mice recovered for 3 days.
PIC injection. After 3 days of recovery (Day 4), the acute antiviral response was
induced by intraperitoneal (i.p.) injection of 12 mg/kg of ultrapure PIC (Invivogen, San
Diego, CA) in saline. Mice injected with 100 µL of saline served as vehicle controls. To
confirm successful i.p. injection, the development of sickness behavior was assessed 3
hours after PIC injection using the rearing test as previously described (Michalovicz &
Konat, 2014; Michalovicz et al., 2015). Briefly, three hours after PIC or saline injection,
mice were placed in an open-field chamber (14.5 in. (H) x 17.5 in. (L)) and allowed to
acclimate for 5 minutes. After 5 minutes, rearing behavior was recorded for 15 minutes.
A decrease in the number of rears was indicative of sickness behavior.
Glutamate recordings in freely-moving mice. Twenty-four hours after PIC
injection (Day5), mice were placed in an observation chamber (14.5 in. (H) x 17.5 in.
(L)), at which time the MEA pedestal was connected to the FAST-16 mkkII system. After
reaching a stable baseline (approximately 30 minutes), tonic glutamate levels, sampled
approximately every 5 to 10 minutes, and spontaneous glutamate transients, sampled
continuously, were measured for 1 hour. For spontaneous glutamate transients, the
FAST16 mkII MATLAB interface was set to continuously detect peaks above a signal to
noise ratio of 2.5 with a moving baseline of 10 points (or 5s) (Hascup et al., 2011).
Because transients were only observed on the glutamate oxidase sites and not the
recording sites, these signals were representative of glutamate and not noise or artifact
(Hascup et al., 2011; Stephens et al., 2014). Measures derived from the MATLAB
interface included tonic (or resting) glutamate (µM) and five transient parameters: 1) area
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under the curve (AUC), 2) transient maximum amplitude (µM), 3) transient duration
(seconds), 4) inter-transient interval (seconds), and (5) transient frequency.
Seizure induction. Because the hyperexcitable phenotype induced by PIC
injection lasts approximately 3 days (Michalovicz & Konat, 2014), seizures were induced
on Days 5, 6, 7, and 8. Briefly, after obtaining pre-seizure glutamate measurements, mice
were subcutaneously (s.c.) injected with 12 mg/kg of kainic acid (KA) to induce status
epilepticus (SE) under continuous glutamate recording. Mice injected with saline (SAL;
50 µL) served as vehicle controls. Seizure severity was graded by blinded observers in 5minute increments. The scores ranged from 0 to 6 broken down as follows: 0, no
response; 1, immobility; 2, rigid posture; 3, scratching/circling/head bobbing; 4, forelimb
clonus/rearing/falling; 5, repetitious pattern 4; 6, severe tonic-clonic seizures (Morrison et
al., 1996). Seizures lasted approximately 100-200 minutes, and glutamate measurements
were recorded throughout this period. Twenty minutes after seizures ceased, post-seizure
glutamate measurements were taken for 10 minutes.
Statistical analyses. Results were evaluated by repeated measures ANOVAs
using JMP (SAS, Cary, NC 27513). Within-subject measures included Day (Days 5-8)
and Phase (pre-seizure, during seizure, and post-seizure). A Grubb’s test was used to
identify outliers. Significant omnibus tests were followed by t-test post hoc comparisons.
Due to the nonlinearity of the data, spearman correlations were also run to determine the
relation between pre-seizure tonic glutamate and seizure scores. Results were presented
as mean ± SEM, and differences between groups were considered statistically significant
at p ≤ 0.05.
Results
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Temporal changes in body weight following microelectrode implantation and PIC
challenge.
Because PIC-challenge induces transient weight loss (Cunningham et al., 2007),
body weight was recorded for the length of the experiment. PIC-challenge induced a
significant decrease in bodyweight 24 h after injection, i.e., Day 5 (Day*Group effect,
F(7,182)=3.08, p=.004; Fig. 3.1]. Bodyweights returned to control levels after 24 h (Day
6), indicating only temporary body weight loss.
The effect of PIC-challenge on glutamate homeostasis.
Our previous work demonstrates that PIC-challenge significantly increases tonic
glutamate levels 24 hours after PIC injection in anesthetized mice (Hunsberger et al.,
2016). To determine whether this increase is transient, the temporal effects of PICchallenge were examined by comparing the PIC-SAL vs. SAL-SAL groups from 24
hours (Day 5) to 96 hours (Day 8) after PIC injection. Tonic glutamate levels were
transiently elevated by PIC-challenge with the highest levels at 24 h (Day 5) (Group
effect, F(1,9)=5.00, p=.05; Fig. 3.2A). PIC-challenge did not significantly alter transient
duration, amplitude, net AUC, inter-transient interval, or transient frequency (p’s>.05;
Fig. 3.2B-F).
The effect of PIC-challenge on KA-induced seizures.
As previously demonstrated in naïve mice (Kirschman et al., 2011; Michalovicz
& Konat, 2014), PIC-challenge also resulted in a transient increase in the susceptibility to
KA-induced seizures in mice implanted with MEA. The average seizure score
(Day*Group effect, F(3,33)=15.98, p=.0001; Fig. 3.3A), seizure duration (Day*Group
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effect, F(3,33)= 14.17, p=.0001; Fig. 3.3B), and cumulative seizure score (Day*Group
effect, F(3,33)=9.74, p=.0001; Fig. 3.3C) were highest 24 hours after PIC injection (Day
5), remained significantly elevated at 48 h (Day 6), and returned to control levels at 72 h
(Day 7). Moreover, repeated daily injections of KA did not change the body weight of the
animals for Days 5-8 (p>.05), indicating no gross adverse effects of the SE (Fig. 3.3D).
To determine if pre-seizure tonic glutamate levels would predict seizure severity,
Spearman correlations analyses were performed using data from Day 5. The results
demonstrate that baseline tonic glutamate levels in the CA1 significantly correlates with
both the average seizure score (R2=.65, p=.02; Fig. 3.4A) and cumulative seizure score
(R2=.87, p=.0002; Fig. 3.4B).
Seizure-induced changes in glutamate homeostasis.
We next sought to determine whether SE changes tonic and transient glutamate in
PIC-challenged (PIC-KA) vs. saline-injected mice (SAL-KA). Following KA-injection,
tonic and transient glutamate levels were measured for the duration of seizures (100-200
min). PIC-challenge significantly increased tonic glutamate levels during seizure [Group
effect, F(1,10)=5.08, p=.04; Fig. 3.5A] with the greatest increase at 24 h (Day 5).
However, PIC-challenge did not significantly alter transient duration, amplitude, net
AUC, inter-transient interval, or transient frequency between the groups during seizure
(p’s>.05; Fig. 3.5B-F).
Our previous data suggest that the most robust cerebral changes occur 24 hours
after PIC injection (Fil et al., 2011; Hunsberger et al., 2016; Michalovicz & Konat, 2014;
Michalovicz et al., 2015). Therefore, 24 hours after PIC injection (Day 5), seizure-
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induced changes in glutamate homeostasis were examined by comparing the PIC-KA and
SAL-KA groups across the 3 phases: pre-seizure, seizure, and post-seizure. For all 3
phases, tonic glutamate levels were significantly increased in PIC-challenged mice
compared to saline-injected controls. In addition, PIC-challenged mice exhibited a
significant increase in tonic levels as a result of seizure induction with KA, whereas the
saline-injected mice did not [Phase*Group effect, F(2,18)=5.7, p=.01; Fig. 3.6A]. There
were no changes in transient duration, amplitude, net AUC, inter-transient interval, or
transient frequency across the 3 phases (p’s>.05; Fig. 3.6B-F).
Discussion
The current study examined the relationship between glutamate homeostasis and
seizure severity after peripheral viral challenge. The work presented here expands on
previous findings that peripheral viral challenge with PIC increases susceptibility to KAinduced seizures as indicated by increased average and cumulative seizure score
(Kirschman et al., 2011) and elevates extracellular tonic glutamate levels in the
hippocampus (Hunsberger et al., 2016). The ability to measure glutamate homeostasis
and seizure behavior in the same animal revealed a strong association between preseizure tonic glutamate levels and seizure severity. Consistent with previous studies
(Michalovicz & Konat, 2014), increased seizure susceptibility in PIC-challenged animals
was highest 24 h after PIC injection and remained elevated for 48 h. Tonic glutamate
levels also gradually declined across days after PIC challenge, which matches the pattern
of inflammatory milieu following this peripheral insult (Fil et al., 2011; G. W. Konat et
al., 2009; Michalovicz & Konat, 2014; Michalovicz et al., 2015).
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Prior to seizure induction, tonic glutamate levels were recorded and found to be
increased 24 hours after PIC-challenge, before gradually decreasing to control levels
across the four days. This transient increase in glutamate 24 h after PIC injection is
congruent with our previous studies in anesthetized mice (Hunsberger et al., 2016) and
may be the result of inflammatory mediators that reach the CNS after PIC insult (Fil et
al., 2011; G. W. Konat et al., 2009; Michalovicz et al., 2015). These inflammatory
mediators can cause changes in excitatory glutamate neurotransmission and inhibitory
GABA transmission that lead to hyperexcitability. For example, cytokines, chemokines,
and complements upregulated after PIC-challenge can increase glutamate receptor
expression and enhance function leading to increased glutamate signaling. In support of
this, mice overexpressing the cytokine, IL-6, exhibit impaired development of inhibitory
synapses and larger excitatory synaptic connections (Wei et al., 2012). Furthermore,
glutamatergic NMDA receptor expression is increased in the presence of IL-1 β (Viviani
et al., 2003), while expression of astrocytic glutamate transporters (GLT-1) is reduced
(Prow & Irani, 2008). The reduction in GLT-1, which removes glutamate from the
extracellular space, may explain the increased tonic glutamate levels observed after PICchallenge.
Compared to our previous study in which the effects of PIC challenge on tonic
glutamate was examined in anesthetized mice (Hunsberger et al., 2016), both PIC- and
saline-treated animals in the current study exhibited approximately 2-fold higher levels of
tonic glutamate. The increase in tonic glutamate levels in the current study may be due to
inflammation resulting from MEA-implantation surgery or because the animal is awake,
as opposed to anesthetized, during glutamate recordings. Examination of glutamate after
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a longer recovery period in future studies may help address the concern regarding
surgery-related inflammation. Although isoflurane anesthesia, used in our previous
experiment, does not likely decrease glutamate levels the way other anesthesias do
(Westphalen & Hemmings, 2003), it is possible that the glutamatergic system is
dampened under anesthesia (Westphalen, Kwak, Daniels, & Hemmings, 2011).
For the first time in the PIC model, glutamate transients were characterized using
the MEA technology. Surprisingly, there were no differences in glutamate transients
between the groups prior to seizure onset. In contrast, a previous study in aged rats
experiencing 4-aminopyridine (4-AP) induced seizures revealed increases in glutamate
transient amplitude and the frequency of glutamate transients that were predictive of
seizure severity (Stephens et al., 2014). However, there are several differences in
experimental design that could have contributed to the contrasting results. Differences
include the use of rats as opposed to mice, injecting 4-AP directly into the hippocampus
instead of a systemic injection of kainic acid, and age of the animals tested (i.e., 8 week
old mice vs. 3-24 month old rats). This latter difference may be particularly important.
Whereas a single injection of PIC induces a transient and acute increase in inflammatory
mediators, aging is associated with chronic increases in proinflammatory cytokine levels
(Michaud et al., 2013). Thus, it is possible that an acute insult (e.g., a single injection of
PIC) may be insufficient to trigger changes in glutamate transient neurotransmission,
despite producing robust alterations in tonic glutamate levels. Future studies examining
the effects of repeated PIC injection on glutamate transients is warranted.
It is possible that glutamate transients are of neuronal origin and are therefore
unaffected by inflammatory mediators produced in response to PIC. In support of this,
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glutamate transient signals are greatly reduced by local application of tetrodotoxin
(TTX), a neurotoxin, or ω-conotoxin, a calcium channel blocker (Hascup et al., 2011; E.
R. Hascup et al., 2010). Because recent evidence shows that astrocytic glutamate release
is not calcium dependent (Agulhon, Fiacco, & McCarthy, 2010), glutamate transient
levels are most likely controlled by neuronal mechanisms.
The most interesting finding of this study may be the relationship between tonic
glutamate levels and seizure severity. These results suggest that inflammatory mediators
produced in response to peripheral inflammation can disrupt glutamate homeostasis and
change functional outcomes as seen from an increase in average seizure score and
cumulative seizure score in PIC-challenged mice. Similar results were observed when
examining pre-seizure tonic glutamate levels and seizure severity after intrahippocampal
injection of 4-AP in aging rats; higher baseline levels of tonic glutamate were predictive
of seizure severity (Stephens et al., 2014). Concurrent with animal studies, human studies
reveal that basal glutamate is elevated in the hippocampus of patients with refractory
temporal lobe epilepsy (During & Spencer, 1993) and that these elevated levels are
related to higher seizure frequency (Cavus et al., 2005). Studies examining tissue from
chronic epileptic patients suggest inflammation may play a role in the pathophysiology of
seizures. For example, increased levels of inflammatory mediators and their receptors are
seen in activated glial cells, neurons, and endothelial cells (Marchi et al., 2010; Ravizza
et al., 2008).
PIC-challenge also resulted in elevated tonic glutamate levels during seizure, an
increase that was exacerbated by KA-induced seizures. Extracellular tonic glutamate is
controlled by the balance of glutamate release and uptake. It is possible that during
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seizure more glutamate is released, however, evidence supports the notion that
inflammatory mediators act on glutamate clearance mechanisms. Specifically, astrocytic
glutamate transporters (GLT-1 and GLAST) are decreased in aged rodents (Brothers et
al., 2013) and in cultures exposed to lipopolysaccharide (LPS), which elicits an antibacterial immune response (Tilleux & Hermans, 2008). Moreover, our previous work
revealed that glutamate clearance is decreased by PIC-challenge and that neuronal
glutamate release mechanisms remain unaffected (Hunsberger et al., 2016). It should be
noted that astrocytes can also release glutamate into the extracellular space, and this
process is enhanced by inflammatory mediators. For example, TNFα is known to increase
synaptic transmission and can stimulate the release of glutamate from astrocytes
(Santello, Bezzi, & Volterra, 2011). Moreover, the cystine/glutamate antiporter, another
potential source of nonsynaptic glutamate, has been implicated in epileptic seizures
(Buckingham et al., 2011), and is upregulated after ischemic injury (Soria et al., 2014),
where inflammation plays an important role in the pathogenesis (Elkind, Cheng, Rundek,
Boden-Albala, & Sacco, 2004; McColl, Rothwell, & Allan, 2007). These additional
sources of extracellular glutamate release in combination with the decrease in glutamate
clearance could potentially impact the amount of glutamate in the extracellular space and
likely contribute to the seizure hypersusceptibility observed in our PIC animals. Future
studies examining glutamate release and uptake during seizure will help to delineate the
role of each in mediating seizure hypersusceptibility in PIC-challenged mice.
Overall, our results provide evidence that peripheral viral challenge results in
altered glutamate homeostasis that is predictive of seizure severity. Build up of
extracellular glutamate following PIC challenge may contribute to the pathology of
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neurodegenerative conditions that are comorbid with peripheral infection, such as
Alzheimer disease and seizures. Therefore, deciphering mechanisms by which peripheral
viral infection elevates extracellular glutamate is critical to the prevention of infectionmediated exacerbations in neurodegenerative conditions.
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Chapter 3 Figures
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Figure 3.1. Temporal changes in body weight following MEA implantation and PIC
challenge. Mice were implanted with MEA pedestals and challenged with 12 mg/kg of
PIC on Day 4 post-surgery. Saline-injected mice served as respective controls. Symbols
represent means ± SEM from 13 to 15 animals. Asterisks denote significant differences
from saline controls (**p≤ .01).
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Figure 3.2. Changes in glutamate homeostasis induced by PIC challenge. Mice
implanted with MEA pedestals were challenged with PIC on Day 4, and extracellular
glutamate was analyzed on Days 5-8. (a) Tonic glutamate levels, (b) glutamate transient
duration, (c) amplitude, (d) area under the curve (AUC), (e) net inter-transient interval
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and (f) transient frequency. Symbols represent means ± SEM from 5 to 7 animals per
group. Asterisks denote significant differences from saline controls (*p≤ .05).
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Figure 3.3. Enhancing effect of PIC-challenge on KA-induced seizures. Mice
implanted with MEA pedestals were challenged with PIC on Day 4 and status epilepticus
(SE) was induced by subcutaneous injection of 12 mg/kg of KA on Days 5, 6, 7 and 8
(PIC-KA group). Mice injected with saline in lieu of PIC served as controls (SAL-KA).
Seizures were expressed as average seizure score (a), seizure duration (b), and cumulative
seizure score (c). Also, the effect of SE on the body weight was monitored (d). Symbols
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represent means ± SEM from 5 to 8 animals per group. Asterisks denote significant
differences from saline controls (**p≤ .01, ***p≤ .001).
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Tonic glutamate was determined in animals described in Fig. 3 before injection of KA.
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These values were plotted against the average (a) and cumulative (b) seizure scores
during SE. The correlation was analyzed by the Spearman’s rank correlation.
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Figure 3.5. SE-induced changes in glutamate homeostasis. SE was induced in mice
implanted with MEA pedestals as in Fig. 3. Tonic glutamate levels (a), duration of
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glutamate transients (b), amplitude of glutamate transients (c), area under the curve
(AUC) (d), net inter-transient interval (e) and transient frequency (f) were monitored.
Symbols represent means ± SEM from 5 to 8 animals per group. Asterisks denote
significant differences between PIC-KA and SAL-KA groups (**p≤ .01).
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Figure 3.6. Temporal changes in glutamate homeostasis induced by SE. Mice
implanted with MEA pedestals were challenged with PIC on Day 4 and status epilepticus
(SE) was induced by KA on Day 5 as in Fig. 3 (PIC-KA group). Mice injected with
saline in lieu of PIC served as respective controls (SAL-KA). Tonic glutamate and
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glutamate transient were measured prior, during, and after SE (for details see M&M). (a)
Tonic glutamate levels (a), glutamate transient duration (b), amplitude (c), area under the
curve (AUC) (d), net inter-transient interval (e), and transient frequency (f). Bars
represent means ± SEM from 5 to 8 animals per group. Asterisks denote significant
differences from saline controls (**p≤ .01, ***p≤ .001). # Symbol denotes significant
differences between pre-seizure and seizure (#p≤ .05).

Chapter 4
Translational significance. Our findings of increased tonic glutamate levels and
synaptic neurotransmission after PIC challenge provide a possible link between
peripheral viral infection and neurodegenerative conditions. We were also able to show
that tonic glutamate levels are predictive of seizure severity, which suggests that
glutamate is playing a role in seizure activity and possibly the hyperexcitability observed
after PIC challenge. Findings of increased hyperexcitability are important because
hyperexcitability is a common feature in many neurodegenerative conditions, such as
Alzheimer’s disease. The elucidation of this link offers new options for therapeutic
approaches to prevent infection-mediated exacerbations in neurodegenerative diseases.
Limitations. In Experiment 1 we observed increased tonic glutamate possibly
resulting from a decrease in glutamate clearance. However, it is difficult to conclude the
mechanisms that are responsible for this decrease in glutamate clearance. Future studies
will need to examine glutamate clearance transporter expression using western blots as
well as using various drugs (e.g., TTX) to block glutamate release mechanisms.
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Furthermore, the use of anesthesia in Experiment 1 may have suppressed glutamate
signaling, however, this limitation was addressed by using awake behaving animals in
Experiment 2.
Although Experiment 2 tonic glutamate levels were consistent with our previous
results, we did observe variability in glutamate transient levels. This variability may have
hindered our ability to observe significant changes and future studies will need to use a
greater sample size. In addition, glass micropipettes can be attached to the implanted
MEAs to measure evoked release and clearance in the awake behaving animals. In
Experiment 2, our MEA setup did not contain a micropipette, as we were primarily
interested in spontaneous glutamate events.
Future Directions. Future work will examine protein changes resulting from
PIC-challenge as well as measuring glutamate changes throughout the whole brain.
Because inhibitory GABA neurotransmission has also been shown to decrease in
response to inflammatory mediators, future studies will measure GABA levels and
receptor expression. To determine if viral challenge can exacerbate neurodegenerative
pathology, repeated administration of PIC will be examined in a transgenic AD mouse
model.
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Supplemental Table
Number of rears
SAL
Experiment 1
71.8
Experiment 2
64.9

PIC
46.7
35.2

Table S1. The average number of rears three hours after saline or PIC injection for
Experiments 1 & 2.
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